Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003675 · ClinicalTrials.gov registry record · Phase 2
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT00003675: Completed Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by Alliance for Clinical Trials in Oncology.
NCT00003675 is a Phase 2 study of Leukemia and Myelodysplastic Syndromes that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 100 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003675, a Phase 2 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of topotecan in treating patients who have myelodysplastic syndrome.
Primary Outcome
Response in the peripheral blood is assessed during tx, q 3 mon for 2 yrs post tx, then annually for another 3 years, and then at progression Bone marrow response is assessed prior to cycle 3, then q 4 cycles for the 1st yr. then q 8 cycles for patients who continue beyond
Conditions Studied
Interventions
- DRUG topotecan hydrochloride
Study Locations (20)
Illinois
- University of Illinois at Chicago Health Sciences Center - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
California
- University of California San Diego Cancer Center - La Jolla
- UCSF Cancer Center and Cancer Research Institute - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
District of Columbia
- Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Missouri
- Veterans Affairs Medical Center - Columbia (Truman Memorial) - Columbia
- Ellis Fischel Cancer Center - Columbia - Columbia
Alabama
- Veterans Affairs Medical Center - Birmingham - Birmingham
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Florida
- CCOP - Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1999-03 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00003675 record still lists
NCT00003675 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which topotecan hydrochloride is the first listed.
NCT00003675 names 20 study sites across 12 states, led by Illinois, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00003675 about?
NCT00003675 is a clinical study titled "Topotecan in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of topotecan in treating patients who have myelodysplastic syndrome.
What is the current status of trial NCT00003675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 1999-03. Estimated completion is 2009-04.
What conditions does trial NCT00003675 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT00003675?
The interventions under investigation include: topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003675?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003675 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003675's enrollment target sits among peer trials
100 59th of 233 higher than 170 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia